T cells plays an essential role in cell-mediated immunity by participating in defending human bodies against foreign pathogens or autologous tumor cells via recognizing specific antigens. Compared to traditional antibodies, the most prominent feature of T-cell receptors is their abilities to target internal tumor antigens presented by MHC molecules. Thus, their therapeutic value is much greater. By integrating a panel of advanced technologies, XLifeSc is able to re-engineer T cell receptors to effectively clear cancer cells both in cell and animal models with minor toxicity. Currently, XLifeSc has established two TCR platforms, including an adoptive T cell immunotherapy (TCR-T) and a HATac protein therapy.